Zevra Therapeutics (ZVRA) Debt to Equity (2014 - 2025)
Zevra Therapeutics (ZVRA) reported Debt to Equity of $0.4 for Q4 2025, down 73.31% on a YoY basis from $1.5 in Q4 2024, and down 13.03% quarter-over-quarter from $0.46 in Q3 2025.
Zevra Therapeutics (ZVRA) Debt to Equity (2014 - 2025) Analysis & Trends
Zevra Therapeutics has reported Debt to Equity for 8 years, with the latest figure at $0.4 in Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity fell 73.31% year-over-year to $0.4; the trailing twelve-month figure through Dec 2025 stood at $0.4 (down 73.31% YoY), and the FY2025 full-year result was $0.4, down 73.31% from the prior year.
- Debt to Equity for Q4 2025 stood at $0.4, down from $0.46 in the prior quarter.
- The five-year high for Debt to Equity was $1.8 in Q2 2024, with the low at $0.01 in Q1 2021.
- Historically, Debt to Equity has averaged $0.72 across 5 years, with a median of $0.6 in 2023.
- Annual changes were most pronounced in 2024 — Debt to Equity soared 923.86% — and 2025, when it plunged 73.31%.
- Zevra Therapeutics' Debt to Equity stood at $0.01 in 2021, then soared by 1372.17% to $0.14 in 2022, then jumped by 406.55% to $0.69 in 2023, then jumped by 117.0% to $1.5 in 2024, then tumbled by 73.31% to $0.4 in 2025.
- The last three Debt to Equity figures came in at $0.4 (Q4 2025), $0.46 (Q3 2025), and $0.52 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.40 |
| Sep 30, 2025 | 0.46 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 1.46 |
| Dec 31, 2024 | 1.50 |
| Sep 30, 2024 | 0.84 |
| Jun 30, 2024 | 1.80 |
| Mar 31, 2024 | 0.78 |
| Dec 31, 2023 | 0.69 |
| Sep 30, 2023 | 0.08 |
| Sep 30, 2022 | 0.14 |
| Mar 31, 2021 | 0.01 |
| Dec 31, 2020 | -0.01 |
| Sep 30, 2020 | -0.01 |
| Jun 30, 2020 | -0.01 |
| Dec 31, 2015 | -1.10 |
| Sep 30, 2015 | -2.01 |
| Jun 30, 2015 | 3.27 |
| Mar 31, 2015 | -0.20 |
| Dec 31, 2014 | -0.22 |